Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.20 - $29.27
Previous CloseN/A
Volume11.83K
Average Volume (3M)75.14K
Market Cap
$315.77M
Enterprise Value-$954.53K
Total Cash (Recent Filing)$74.87M
Total Debt (Recent Filing)$16.36M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Mar 31, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.61
Shares Outstanding11,221,307
10 Day Avg. Volume120,434
30 Day Avg. Volume75,139
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)42.95
Price to Cash Flow (P/CF)63.60
P/FCF Ratio63.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$44.17Price Target Upside58.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Palvella Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 SELVA trial has been granted Breakthrough Designation, Fast Track Designation, and Orphan Drug Designation by the FDA.
Competitive PositioningAnalyst came away more positive on PVLA’s future competitive positioning relative to other medicines in the mLM landscape.
Bears Say
Industry RisksPVLA is subject to standard biotech industry risks, including clinical, financing, intellectual property, and regulatory risks.
Market CompetitionRare dermatology is an attractive area for biotech due to significant unmet needs, pricing power, and minimal competition.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.52% Insiders
0.16% Mutual Funds
29.15% Other Institutional Investors
67.05% Public Companies and
Individual Investors
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $6.20 and its highest was $29.27 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $315.77M.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is in 6 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on May 08, 2024. The company reported -$3.954 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.954.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.63.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,221,307 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$3.954 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.906%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
---
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.17 (58.49% Upside)
$44.17 (58.49% Upside)
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 42.1%
Last 30 Days ▲ 42.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.96%
12-Months-Change
Fundamentals
Return on Equity
-68.21%
Trailing 12-Months
Asset Growth
-65.44%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
---
PVLA Stock 12 Month Forecast
Average Price Target
$44.17
▲(58.49% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering PVLA
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+114.63%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +114.63% per trade.
---